ArticleRheumatology (Oxford, England)2026
Impact of comorbidities and extra-musculoskeletal manifestations on radiographic progression in ankylosing spondylitis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo examine whether baseline comorbidity burden and extra-musculoskeletal manifestations (EMMs)-psoriasis, uveitis, IBD-are associated with spinal radiographic progression in AS.
methodsWe analysed participants fulfilling modified New York criteria with one or more lateral cervical or lumbar radiograph. Radiographic progression was quantified using the modified Stoke AS Severity Score (mSASSS), excluding score 1 at each vertebral corner (range 0-48). Comorbidity count (22 self-reported conditions: none, one, two, three or more) and ever-presence of each EMM at baseline were exposures. mSASSS change over time with exposure-time interactions was modelled using generalized estimating equations; coefficients were rescaled to represent mean difference in progression (units/10 years). Models adjusted for baseline mSASSS, sex, symptom duration, CRP, HLA-B27, smoking, TNF inhibitor use, and number of EMMs or comorbidity count. Secondary analyses examined potential sex- and segment-specific effects.
resultsAmong 1150 individuals (mean age 44 years; 75% male; 84% HLA-B27 positive), 3441 patient-years were analysed (median follow-up 2 years; median two radiographs). Compared with those with no comorbidities, progression was greater amongst patients with two (2.7 units/10 years; 95% CI 1.9-3.5) and three or more (2.3; 1.5-3.1) comorbidities. Uveitis (2.2 units/10 years; 1.3-3.0) and psoriasis (2.4 units/10 years; 1.4-3.5), but not IBD, were associated with greater progression. Sex-specific analyses suggested greater spinal progression in females than males with psoriasis. Cervical-predominant changes were seen with uveitis and psoriasis.
conclusionComorbidity burden, uveitis and psoriasis are independently associated with greater spinal radiographic progression in AS. These readily identifiable features may inform risk stratification and targeted management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.